PharmaCielo Makes First CBD Shipment to Europe

TORONTO and CHAM, SwitzerlandAug. 19, 2019 /CNW/ – PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., confirmed today it successfully completed the first commercial export of CBD isolate to Europe.

The inaugural shipment of the high quality CBD isolate, a key ingredient in various cannabis derived therapeutic, nutraceutical, topicals and lifestyle products, was delivered to the Swiss headquarters of Creso Pharma, a global pharmaceutical with expertise in cannabis- and hemp-derived products for human and veterinarian use. This comes on the heels of the Colombian government granting the first commercial CBD isolate exporting permit to PharmaCielo, as announced on July 25, 2019.

"This inaugural shipment is symbolic on many levels. PharmaCielo is the first medicinal cannabis company to commercially export cannabis derived isolates from Colombia to Switzerland – the global capital of the pharma industry. Particularly pleasing is the fact that the first batch we ever exported went to Creso Pharma, our trusted partner soon to be part of our Company," said David Attard, CEO at PharmaCielo Ltd. "PharmaCielo's ability to successfully navigate the complex exporting process gives us a tremendous advantage in the market, as required for continuing exports from Colombia of cannabis derived extracts and crystals. It also demonstrates the synergies between the Company and Creso Pharma that will be realized and augmented once the acquisition closes."

The collaboration between PharmaCielo and Creso Pharma spans beyond the current and future supply of cannabis isolate and oil extracts. PharmaCielo recently announced a multi-country sales agreement with Uruguay-based Laboratorios Adler in which the Company will supply both PharmaCielo produced CBD isolate and Creso Pharma's veterinarian CBD complementary feed range of products to Adler for distribution in UruguayParaguayBolivia and Southern Brazil.

"PharmaCielo's CBD isolate meets the highest purity standards in the industry, a critical element that aligns with our commitment to develop and produce the highest quality cannabis-based therapeutic and nutraceutical products for humans and animals."

– Dr. Miri Halperin Wernli, Co-Founder and Chief Executive Officer with Creso Pharma.

Wernli went on to state that "PharmaCielo's unparalleled cultivation of proprietary varieties, when combined with recently expanded production capabilities, produces high quality isolate and oil extracts in an unmatched, and winning, offering."

Disclaimer: Past performance is not an indicator of future performance.

About PharmaCielo

PharmaCielo Ltd. (TSXV:PCLO, OTC:PHCEF ) is a global company, headquartered in Canada, with a focus on ethical and sustainable processing and supplying of all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo's principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its nursery and propagation centre located in Rionegro, Colombia.

The boards of directors and executive teams of both PharmaCielo and PharmaCielo Colombia Holdings are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia's ideal location will play in building a sustainable business in the medical cannabis industry, and the Company, together with its directors and executives, is executing on a business plan focused on supplying the international marketplace.

Subscribe Now
& Keep Up to Date

Get the latest pot stock recommendations, cannabis news
and industry updates straight to your inbox!

Louis O'Neill
Louis O'Neill

Louis is a writer based in Sydney with a focus on social and political issues. Having interviewed local politicians and entrepreneurs, Louis now focuses on cannabis culture, legislation & reform.

Leave a Reply

Your email address will not be published. Required fields are marked *